Database of articles cited by EMDB/PDB/SASBDB data

Keywords
Structure methods	All X-ray diffraction NMR electron microscopy small angle scattering neutron diffraction fiber diffraction powder diffraction infrared spectroscopy EPR fluorescence transfer theoretical model Hybrid
Author
Journal
IF	>30 >20 >10 >5 all

Title	Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914.
Journal, issue, pages	Structure, Vol. 23, Page 407-417, Year 2015
Publish date	Jul 14, 2014 (structure data deposition date)
Authors	Huber, E.M. / Heinemeyer, W. / Groll, M.
External links	Structure / PubMed:25599643
Methods	X-ray diffraction
Resolution	2.3 - 3.1 Å
Structure data	PDB-4qux: yCP beta5-A49T-mutant Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4quy: yCP beta5-A49S-mutant Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qv0: yCP beta5-A49T-A50V-double mutant Method: X-RAY DIFFRACTION / Resolution: 3.1 Å PDB-4qv1: yCP beta5-M45A mutant Method: X-RAY DIFFRACTION / Resolution: 2.5 Å PDB-4qv3: yCP beta5-M45V mutant Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qv4: yCP beta5-M45T mutant Method: X-RAY DIFFRACTION / Resolution: 2.7 Å PDB-4qv5: yCP beta5-M45I mutant Method: X-RAY DIFFRACTION / Resolution: 2.7 Å PDB-4qv6: yCP beta5-A49V mutant Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qv7: yCP beta5-A50V mutant Method: X-RAY DIFFRACTION / Resolution: 2.6 Å PDB-4qv8: yCP beta5-C52F mutant Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qv9: yCP beta5-C63F mutant Method: X-RAY DIFFRACTION / Resolution: 2.6 Å PDB-4qvl: yCP in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qvm: yCP beta5-M45A mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qvn: yCP beta5-M45V mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qvp: yCP beta5-M45T mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.3 Å PDB-4qvq: yCP beta5-M45I mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.6 Å PDB-4qvv: yCP beta5-A49V mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qvw: yCP beta5-A49S-mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qvy: yCP beta5-A49T-mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.51 Å PDB-4qw0: yCP beta5-A49T-A50V-double mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qw1: yCP beta5-A50V mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qw3: yCP beta5-C63F mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qw4: yCP in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qw5: yCP beta5-M45A mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qw6: yCP beta5-M45V mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qw7: yCP beta5-M45T mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 2.7 Å PDB-4qwf: yCP beta5-M45I mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qwg: yCP beta5-A49V mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 2.6 Å PDB-4qwi: yCP beta5-A49S-mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 2.6 Å PDB-4qwj: yCP beta5-A49T-mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qwk: yCP beta5-A49T-A50V-double mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qwl: yCP beta5-A50V mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 2.6 Å PDB-4qwr: yCP beta5-C52F mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qws: yCP beta5-C63F mutant in complex with carfilzomib Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qwu: yCP beta5-C52F mutant in complex with bortezomib Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qwx: yCP in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qxj: yCP beta5-M45A mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qz0: yCP beta5-M45V mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qz1: yCP beta5-M45T mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qz2: yCP beta5-M45I mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 2.7 Å PDB-4qz3: yCP beta5-A49V mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qz4: yCP beta5-A49S mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qz5: yCP beta5-A49T-mutant in complex with ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qz6: yCP beta5-A49T-A50V double mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4qz7: yCP beta5-A50V mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 2.8 Å PDB-4qzw: yCP beta5-C52F mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 3 Å PDB-4qzx: yCP beta5-C63F mutant in complex with the epoxyketone inhibitor ONX 0914 Method: X-RAY DIFFRACTION / Resolution: 2.6 Å PDB-4qzz: yCP in complex with Omuralide Method: X-RAY DIFFRACTION / Resolution: 2.9 Å PDB-4r00: yCP beta5-C52F mutant in complex with Omuralide Method: X-RAY DIFFRACTION / Resolution: 2.8 Å
Chemicals	ChemComp-MG: Unknown entry ChemComp-HOH: WATER ChemComp-CL: Unknown entry ChemComp-BO2: N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE / medication, anticancerYM ChemComp-3BV: N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-phenylalaninamide / medication, anticancer, inhibitorYM ChemComp-MES: 2-(N-MORPHOLINO)-ETHANESULFONIC ACID / pH bufferYM ChemComp-04C: 1,2,4-trideoxy-4-methyl-2-{[N-(morpholin-4-ylacetyl)-L-alanyl-O-methyl-L-tyrosyl]amino}-1-phenyl-D-xylitol ChemComp-NA: Unknown entry ChemComp-SLA*: Omuralide, open form
Source	saccharomyces cerevisiae (brewer's yeast)
Keywords	HYDROLASE / Cancer / Proteasome / Bortezomib / Drug Resistance / Binding Analysis / HYDROLASE/HYDROLASE INHIBITOR / HYDROLASE-HYDROLASE INHIBITOR complex